ENVB Stock — Enveric Biosciences Inc

Enveric Biosciences Inc (ENVB)

Updated October 16, 2026.

ENVB is a Stock. Its deepest 1-year drawdown was 87.7%.

Enveric Biosciences is a biotechnology company developing small molecule neuroplastogenic therapeutics for psychiatric and neurological disorders, with a lead drug candidate in EB-003, a novel DMT derivative in preclinical development, alongside other compounds targeting addiction and neuropsychiatric conditions. The company does not currently distribute to shareholders. Enveric appeals to investors seeking exposure to early-stage biotech development with a focus on novel mental health treatments.

ENVB performance

Returns are updating. ENVB's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 87.7%.

ENVB key facts

Asset type

Stock

Asset class

Equity

Inception date

08/22/1995

Distribution frequency

None

Last close

$1.38 (as of 2026-10-16)

Market cap

$6,176,720

Average volume

22525.0

Last known dates

ex 04/23/2008; payment 11/25/2019

Date quality

Unmatched ex / payment pair — not a live schedule

Beta

1.18

Payout ratio

0.0%

Forward P/E

23.0947

EPS

$-13.01

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ENVB risks and drawbacks

The deepest 1-year drawdown on record here is 87.7%.

Who may consider ENVB — and who may not

It is a weaker fit for investors who need monthly cash flow (ENVB does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on ENVB

• All tickers starting with E

Tagged: Healthcare.

Frequently asked questions